Bristol Myers Squibb
Building a leading biopharma company
Bristol Myers Squibb was on the verge of a momentous deal—the acquisition of Celgene, a leading biotech company. Company leadership believed that the integration of Celgene would create a new and better entity, so they decided to explore a new visual identity and brand voice. The new brand needed to signal a giant leap forward and symbolize a new era for Bristol Myers Squibb as a diversified specialty biopharma leader.
While most people have heard of Bristol Myers Squibb, the company has evolved a great deal since its last corporate rebrand in 1989. The brand needed to make three significant shifts—refocus its story so that it was clear the patient is at the heart of everything it does; elevate the experience of engaging with Bristol Myers Squibb as a whole; and redefine the brand’s voice, making it feel more personal.
In March 2020, Bristol Myers Squibb launched its new corporate brand. The new branding includes several changes—a color change to purple, a stylized hand in the logo, a new font, and the removal of the hyphen in “Bristol-Myers.” These elements combined reflect the new Bristol Myers Squibb, representing its commitment to compassionate science and putting patients first.
The elegant gray wordmark was drawn and exclusively customized for Bristol Myers Squibb. The condensed letterforms are rigorous and precise. Tall, strong and proud, the logo establishes Bristol Myers Squibb as a leader with real gravitas.
Purple acts as a purposeful accent to highlight a benefit from Bristol Myers Squibb, or to create a close connection between patients, people and science. It calls attention to key data and provides direction in digital applications through elements such as buttons and website navigation
Our secondary palette complements the core palette with an ambient set of colors, designed to evoke feelings of comfort and security. This secondary palette consists of color washes that we refer to as “the color of humanity.” It’s meant to represent a diverse range of lives, stories and individual experiences.
We needed something that was fresh, more representative of who we are and who we will be in the future. So, we started from scratch. We didn’t try to put new wheels on to fix something that wasn’t working, we started from ground up.
Kathryn Metcalfe, Executive Vice President, Bristol Myers Squibb